Showing results (431-440 of 974) with videos related to

Sort By:
Pageof 98
Translational Oncology|June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitorsVatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
The Oncologist|May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Oncoimmunology|June 15, 2018
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapyOsama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, et al.
Clinical Lung Cancer|May 27, 2022
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening PopulationHarris Majeed, Hong Zhu, Sarah A Williams, et al.
Journal for Immunotherapy of Cancer|October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancerPrithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerD E Gerber, L Horn, M Boyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 26, 2024
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net PopulationSofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, et al.
Science Translational Medicine|April 9, 2010
Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndromeB L Loeys, E E Gerber, D Riegert-Johnson, et al.
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Pageof 98